Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism

Background: Hypersplenism due to chemotherapy-related liver injury has been associated with severe thrombocytopenia that may preclude continuation of systemic therapy for cancer patients. Patients treated for metastatic colorectal cancer (mCRC) are among the most common patients affected by hyperspl...

Full description

Bibliographic Details
Main Authors: David A. Litvak, Salman Malad, Robert A. Wascher, Maurie Markman, Jiaxin Niu
Format: Article
Language:English
Published: Karger Publishers 2012-11-01
Series:Case Reports in Oncology
Subjects:
Online Access:http://www.karger.com/Article/FullText/345413
_version_ 1819209977257000960
author David A. Litvak
Salman Malad
Robert A. Wascher
Maurie Markman
Jiaxin Niu
author_facet David A. Litvak
Salman Malad
Robert A. Wascher
Maurie Markman
Jiaxin Niu
author_sort David A. Litvak
collection DOAJ
description Background: Hypersplenism due to chemotherapy-related liver injury has been associated with severe thrombocytopenia that may preclude continuation of systemic therapy for cancer patients. Patients treated for metastatic colorectal cancer (mCRC) are among the most common patients affected by hypersplenism. Cessation of systemic therapy invariably leads to progression of disease. While partial splenic embolization has been employed successfully to reverse the effects of hypersplenism, the role of laparoscopic splenectomy for this problem has not been completely defined. Methods: A retrospective review was conducted of mCRC patients treated with laparoscopic splenectomy at our institution to reverse severe thrombocytopenia due to chemotherapy-related hypersplenism. An endpoint assessed was the ability to resume therapy after splenectomy. Results: Six patients with mCRC and hypersplenism requiring cessation of systemic therapy underwent laparoscopic splenectomy. All (6) patients had a postsurgical platelet count >150 × 103/µl and resumed chemotherapy after surgery. Median platelet count prior to surgery was 66 × 103/µl, and just prior to resuming systemic therapy it was 399.5 × 103/µl. Median spleen size was 14.0 cm. There were no surgical complications. Mean hospital stay was 2.8 days and the median time from surgery to resumption of therapy was 23.5 days. Conclusions: Laparoscopic splenectomy appears to offer selected patients with mCRC the opportunity to resume systemic therapy that otherwise would be discontinued due to thrombocytopenia from hypersplenism.
first_indexed 2024-12-23T06:03:51Z
format Article
id doaj.art-2cc551c95b6c4199ab158622cf8a3b99
institution Directory Open Access Journal
issn 1662-6575
language English
last_indexed 2024-12-23T06:03:51Z
publishDate 2012-11-01
publisher Karger Publishers
record_format Article
series Case Reports in Oncology
spelling doaj.art-2cc551c95b6c4199ab158622cf8a3b992022-12-21T17:57:37ZengKarger PublishersCase Reports in Oncology1662-65752012-11-015360160710.1159/000345413345413Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to HypersplenismDavid A. LitvakSalman MaladRobert A. WascherMaurie MarkmanJiaxin NiuBackground: Hypersplenism due to chemotherapy-related liver injury has been associated with severe thrombocytopenia that may preclude continuation of systemic therapy for cancer patients. Patients treated for metastatic colorectal cancer (mCRC) are among the most common patients affected by hypersplenism. Cessation of systemic therapy invariably leads to progression of disease. While partial splenic embolization has been employed successfully to reverse the effects of hypersplenism, the role of laparoscopic splenectomy for this problem has not been completely defined. Methods: A retrospective review was conducted of mCRC patients treated with laparoscopic splenectomy at our institution to reverse severe thrombocytopenia due to chemotherapy-related hypersplenism. An endpoint assessed was the ability to resume therapy after splenectomy. Results: Six patients with mCRC and hypersplenism requiring cessation of systemic therapy underwent laparoscopic splenectomy. All (6) patients had a postsurgical platelet count >150 × 103/µl and resumed chemotherapy after surgery. Median platelet count prior to surgery was 66 × 103/µl, and just prior to resuming systemic therapy it was 399.5 × 103/µl. Median spleen size was 14.0 cm. There were no surgical complications. Mean hospital stay was 2.8 days and the median time from surgery to resumption of therapy was 23.5 days. Conclusions: Laparoscopic splenectomy appears to offer selected patients with mCRC the opportunity to resume systemic therapy that otherwise would be discontinued due to thrombocytopenia from hypersplenism.http://www.karger.com/Article/FullText/345413Laparoscopic surgerySplenectomyHypersplenismSplenomegalyThrombocytopeniaColorectal cancerNeoplasm metastasis
spellingShingle David A. Litvak
Salman Malad
Robert A. Wascher
Maurie Markman
Jiaxin Niu
Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism
Case Reports in Oncology
Laparoscopic surgery
Splenectomy
Hypersplenism
Splenomegaly
Thrombocytopenia
Colorectal cancer
Neoplasm metastasis
title Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism
title_full Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism
title_fullStr Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism
title_full_unstemmed Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism
title_short Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism
title_sort laparoscopic splenectomy in colorectal cancer patients with chemotherapy associated thrombocytopenia due to hypersplenism
topic Laparoscopic surgery
Splenectomy
Hypersplenism
Splenomegaly
Thrombocytopenia
Colorectal cancer
Neoplasm metastasis
url http://www.karger.com/Article/FullText/345413
work_keys_str_mv AT davidalitvak laparoscopicsplenectomyincolorectalcancerpatientswithchemotherapyassociatedthrombocytopeniaduetohypersplenism
AT salmanmalad laparoscopicsplenectomyincolorectalcancerpatientswithchemotherapyassociatedthrombocytopeniaduetohypersplenism
AT robertawascher laparoscopicsplenectomyincolorectalcancerpatientswithchemotherapyassociatedthrombocytopeniaduetohypersplenism
AT mauriemarkman laparoscopicsplenectomyincolorectalcancerpatientswithchemotherapyassociatedthrombocytopeniaduetohypersplenism
AT jiaxinniu laparoscopicsplenectomyincolorectalcancerpatientswithchemotherapyassociatedthrombocytopeniaduetohypersplenism